Infliximab and adalimumab for the treatment of Crohn's disease

  • Technology appraisal guidance
  • TA187
  • Published: 
Download guidance (PDF)

8 Review of guidance

The guidance on this technology will be considered for review by the Guidance Executive in September 2011. NICE welcomes comment on this proposed date. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
May 2010